Does hormone replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies: Part 5. Trends in breast cancer incidence in relation to the use of HRT

Journal of Family Planning and Reproductive Health Care

Volumn 39, Issue 2, 2013, Pages 80-88

  Shapiro, Samuel ^a   Farmer, Richard D T ^b   Stevenson, John C ^c   Burger, Henry G ^d,e   Mueck, Alfred O ^f   Gompel, Anne ^g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d MONASH MEDICAL CENTRE   (Australia)

^e Jean Hailes Medical Centre for Women   (Australia)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER SCREENING; CAUSAL ATTRIBUTION; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ADVERSE EFFECTS; BREAST NEOPLASMS; CAUSALITY; CHEMICALLY INDUCED; UTILIZATION;

BREAST NEOPLASMS; CAUSALITY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS;

EID: 84875136375     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2012-100508     Document Type: Article

References (59)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
3. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
4. The Women's Health Initiative Steering Committee. Effect of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
5. Stefanick ML, Chlebowski RT, Manson JE, et al. Effects of conjugated equine estrogens on breast cancer and mammographic screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-1657.
6. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-1314.
7. Shapiro S, Farmer RDT, Seaman H, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 1. The Collaborative Reanalysis. J Fam Plann Reprod Health Care 2011; 37:103-109.
8. Shapiro S, Farmer RDT, Mueck AO, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 2. The Women's Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care 2011;37:165-172.
9. Shapiro S, Farmer RDT, Seaman H, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 3. The Women's Health Initiative: unopposed estrogen. J Fam Plann Reprod Health Care 2011;37:225-230.
10. Shapiro S, Farmer RDT, Seaman H, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 4. The Million Women Study. J Fam Plann Reprod Health Care 2012;38:102-109.
11. Haas JS, Kaplan CP, Greenberger MS, et al. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Int Med 2007;140:184-188.
12. Ravdin PM, Cronin KS, Howlader N, et al. Reduced hormone therapy use might be cause of steep decline in breast cancer cases. Abstract presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 14 December 2006.
13. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in incidence of breast cancer in the United States. N Engl J Med 2007;356:16:1670-1674.
14. Clarke C, Glaser SL, Uratsu CS, et al. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population evidence. J Clin Oncol 2006;33:e49-e50.
15. Gompel A, Plu-Bureau G. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann NY Acad Sci 2010;1205:268-276.
16. Pelucchi C, Levi F, La Vecchia C. The rise and fall in menopausal therapy and breast cancer incidence. Breast 2010;19:198-201.
17. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of Carcinogenic Risks to Humans: Tobacco Smoke and Involuntary Smoking (Volume 83). Lyon, France: IARC, 2004.
18. Susser M. Causal Thinking in the Health Sciences. New York, NY: Oxford University Press, 1979.
19. US Depart of Health, Education and Welfare: Public Health Service. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service (Public Health Service Publication No. 11030). Washington, DC: US Government Printing Office, 1964.
20. Hill AB. The environment and disease: association or causation? Proc Royal Soc Med 1965;58:295-300.
21. Susser M. What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol 1991;133:635-648.
22. Colditz GA. Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res 2007;9:108-111.
23. Sprague BL, Trentham-Dietz A, Remington PL. The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. Cancer Causes Control 2011;22:125-134.
24. Smith IE, Dowsett M, Ebbs Sr, et al., IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrazole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-5116.
25. Cady B, Chung MA, Michaelson JS. A decline in breast cancer incidence. New Engl J Med 2007;357:511.
26. Ravdin PM, Cronin KA, Chlebowski RT. The authors reply. N Engl J Med 2007;337:513.
27. Greendale GA, Reboussin BA, Sie A, et al. Effect of estrogen and of estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann In Med 1999;130:262-269.
28. Porter PL, El-Basstawissi AY, Mandelson MT, et al. Breast cancer tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999;91:2020-2028.
29. Kerlikowske K,Miglioretti DL, Buist DS, et al. Declines in breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007;99:1-5.
30. Breen N, Cronin KA, Meissner HI, et al. Reported drop in mammography. Is this cause for concern? Cancer 2007;109:2405-2409.
31. Glass AG, Lacey JV, Carreon D, et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-1161.
32. Caan B, Habel L, Quesenberry C, et al. Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2008;100:597-598.
33. Shapiro S. Commentary: Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939-945.
34. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007;26:3437-3439.
35. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of Carcinogenic Risks to Humans: Tobacco Smoke and Involuntary Smoking (Volume 72). Lyon, France: IARC, 1999.
36. DeSantis C, Howlader N, Cronin K, et al. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev 2102;20:733-739.
37. Jemal A, Ward E, Thun M. Recent trends in breast cancer incidence rate by age and tumor characteristics in U.S. women. Breast Cancer Res 2007;9:R28.
38. Li CI, Roger EM, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Int Med 2003;163:2149-2153.
39. Kliewer EV, Demers AA, Nugent ZJ. A decline in breast cancer incidence. N Engl J Med 2007;357:509-510.
40. Canfell K, Banks E, Moa AM, et al. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Austral 2008;188:641-644.
41. Canfell K, Banks E, Clements M, et al. Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res Treat 2009;117:671-673.
42. Australian Institute of Health and Welfare. Cancer Incidence Projections: Australia 2011-2020 (Cancer Series No. 66). Canberra, Australia: Australian Institute of Health and Welfare, 2012;31-33.
43. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilization of hormone replacement therapy. Breast Cancer Res Treat 2007;107:427-430.
44. Mueck AO, Wallwiener D. Brusrtkrebsrate und HRT-verordnungen: differierende daten aus USA und Europa. Frauenarzt 2007;48:812-817.
45. Levi F, Randombison I, Choffat R. Cancer incidence in Vaud, Switzerland (1998-2002). In: Curado MP, Edwards B, Shin JMR, et al. (eds). Cancer Incidence in Five Continents. IARC Scientific Publications No. 160, Vol. DC. Lyon, France: IARC, 2007:369-377.
46. Verkooijen HM, Koot VC, Fioretta R, et al. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 2008;120:519-523.
47. Bouchardy CM, Usel H, Verkooijen C, et al. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat 2010;120:519-523.
48. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in the UK related to changes in use of hormone replacement therapy? Eur J Cancer 2009;45:1649-1653.
49. Zahl BH, Maehlen J. A decline in breast cancer incidence. N Engl J Med 2007;357:510-511.
50. Kumle M. Declining breast cancer incidence and decreased HRTuse. Lancet 2008;372:608-610.
51. Allemand H, Seradour B, Weill A, et al. Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer 2008;95:11-15.
52. Seradour B, Allemand H,Weill A. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 2009;96:E1-E66.
53. Soerjomataram I, Coebergh JW, LouwmanMW, et al. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? J Clin Oncol 2007;25: 5038-5039.
54. Vankrunkelsven P, Keilen E, Louisbergh D, et al. Reduction in hormone replacement therapy and declining breast cancer incidence the Belgian province of Limburg. Breast Cancer Res Treat 2009;118:425-432.
55. Silverman BG, Siegelmann-Danieli N, Braunstein R, et al. Trends in breast cancer incidence associated with reductions in the use of hormone replacement therapy. Cancer Epidemiol 2010;35:11-16.
56. Hemminki E, Kyyronen P, Pukkala E. Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. Maturitas 2008;61:299-304.
57. Seeger H, Wallwiener D, Kraemer E, et al. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 2006;54:72-77.
58. Mueck A, Seeger H. 2-Methoxyestradiol - biology and mechanism of action. Steroids 2010;75:625-631.
59. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005;20: 2052-2060.